Notable clinical trials this century have demonstrated significant clinical activity with targeted therapeutic approaches for several tumor types, including cetuximab for epidermal growth factor receptor (EGFR)-mutant colorectal cancer [22], vemurafenib for B-Raf proto-oncogene (BRAF)-mutant melanoma [29], and olaparib for HRD-enriched ovarian cancers [24], as well as gefitinib and sotorasib for non-small cell lung cancers harboring EGFR or KRAS p.G12C mutations, respectively [20,23]. This evidence concerns the gene EGFR and ovarian carcinoma.